Objectives: to describe primary care pharmacists' current scope of practice in relation to laboratory testing.
Introduction
Pharmacists are easily accessible, trusted frontline primary health care providers who see patients more frequently than any other health care professional. 1, 2 As such, they are well positioned to identify at-risk or poorly controlled patients and Jacqueline Donovan
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work with them to assist in their disease management. To perform this role in the best way possible, pharmacists must gather and interpret appropriate information (i.e., clinical parameters) to determine the best course of action for improving the patients' outcomes. 3 Currently, primary care pharmacists can obtain these clinical parameters by referring a patient to a physician for follow-up diagnostic testing (e.g., laboratory testing) and/or conducting in-pharmacy point-ofcare testing (PoCT) for a narrow range of selected measures 4 and in-pharmacy noninvasive testing (e.g., spirometry, blood pressure monitoring). 5 Currently, pharmaceutical care provision is heavily limited by the reliance on the referral of patients back to physicians for most laboratory tests. Such processes could be made more efficient if pharmacists had the ability to access and order those tests. The ability to access laboratory tests can be defined by one's authority to access and interpret patient laboratory data that have already been ordered. The ability to order, and subsequently access, laboratory data can be defined by one's authority to directly order laboratory tests for a patient. At present, most hospital or inpatient pharmacists around the world have the ability to access laboratory tests and use them to inform their clinical decisions. However, this is rarely the case for pharmacists who practise outside the hospital. 6 Primary care pharmacists' full scope of practice should encompass prescribing, either within a collaborative practice agreement or via supplementary and independent models, as well as the ability to access and order laboratory tests. [7] [8] [9] [10] [11] [12] [13] Primary care pharmacists' scope of practice depends on the jurisdiction they practise in. In addition to dispensing medications and providing medicine-related information to patients and health care providers, primary care pharmacists with relevant qualifications are also providing medication reviews, vaccination services, services for ambulatory conditions and integrating into primary health care teams.
9, [14] [15] [16] [17] Further to these practices, prescriptive and laboratory testing authorities are within primary care pharmacists' scope, and many jurisdictions are moving towards utilizing this full scope of expertise. In Canada, this includes independent or collaborative prescriptive and/or laboratory testing authorities, depending on province/territory.
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In the United States, primary care pharmacists are involved in collaborative drug therapy management and disease state management, which may involve prescriptive and/or laboratory testing authorities, depending on state and agreement. 16 In the United Kingdom, primary care
pharmacists have prescriptive and laboratory testing authorities through supplementary or independent models. 14 In New Zealand, primary care pharmacists within health care teams have independent prescriptive and laboratory testing authorities. 9 Primary care pharmacists in Australia are not currently practising to their full scope of expertise with regards to prescriptive and laboratory testing authorities. 17 The current literature
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• As prescribing authority for pharmacists expands, opportunities exist to use primary care pharmacists' full scope of practice, including the ability to access and order laboratory testing and to develop standardized guidelines, frameworks and standards.
• Primary care pharmacists' scope of practice in laboratory testing is presently limited to certain jurisdictions and is often performed in a dependent fashion.
• there is also a lack of literature explicitly exploring primary care
pharmacists' scope of practice in relation to laboratory testing. Future research should focus on exploring this area of pharmacy practice.
• Primary care pharmacists' involvement in laboratory testing has the potential to improve patient outcomes by facilitating prescribing and potentially reducing medication-related errors.
MIsE EN PrAtIQUE DEs cONNAIssANcEs
• tandis que le pouvoir de prescription des pharmaciens s'étend, il existe des occasions de recourir à toutes les compétences des pharmaciens de soins primaires, notamment la possibilité d'accéder à des analyses de laboratoire et de demander de telles analyses, ainsi que d'élaborer des normes, des lignes directrices et des cadres normalisés.
• Le champ de pratique des pharmaciens de soins primaires relativement aux analyses de laboratoire est actuellement limité à certains territoires, souvent de manière dépendante.
• Il existe également peu de recherches se penchant explicitement sur le champ pratique des pharmaciens de soins primaires relativement aux analyses de laboratoire. Les recherches futures devraient s'attacher à examiner ce domaine de la pratique pharmaceutique.
• La participation des pharmaciens de soins primaires aux analyses de laboratoire pourrait améliorer la santé des patients en simplifiant la prescription et en réduisant éventuellement les erreurs de médicaments.
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describes pharmacists' scope of practice in relation to prescribing medication and demonstrates the positive impact this has on patient outcomes and satisfaction. 18, 19 However, there are limited subsequent publications reporting on pharmacists' scope of practice in relation to laboratory testing. Therefore, the purpose of this review was to identify, describe and compare primary care pharmacists' current scope of practice in relation to accessing and ordering laboratory tests.
Methods

Search strategy
A 2-tiered search strategy was employed ( Figure  1 20, 21 ).
Study selection
All publications identified through the search strategy were evaluated for inclusion in the review. To meet the selection criteria for inclusion, the following had to be met: 1) intervention studies, qualitative studies (including surveys and questionnaires) or grey literature; 2) publications containing information on pharmacists' scope in relation to laboratory testing (i.e., any mention and/or description of pharmacists ordering and/or accessing laboratory tests as a component of the publication); and 3) central laboratory testing. Publications were excluded if they exclusively evaluated 1) PoCT, 2) training for pharmacists in laboratory testing and 3) inpatient hospital pharmacists.
Data extraction
Jurisdictions were categorized into the following based on the primary care pharmacists' authority to access and/or order laboratory tests:
• 
×100
Primary care pharmacists were defined as pharmacists practising in any setting except hospital inpatient, industry, academia or government agency. All primary care pharmacists within jurisdictions that grant independent authority to access and/or order laboratory testing were assumed to be using this authority. An estimate for the 5 countries reviewed was calculated.
Results
Our database search identified 3540 publications, of which 3512 were excluded because of irrelevance to objectives, 3 were exclusively evaluating PoCT or training and 5 were duplicates. Our grey literature search identified 13 publications for inclusion. Therefore, 33 publications were included in this review (Table 1) . These publications were sourced from 4 countries. Most were from the United States (18) and Canada (12), with the remainder from the United Kingdom (2) and New Zealand (1) and none from Australia (0). The literature comprised quantitative (15) and qualitative (5) studies, as well as grey literature, such as practice guidelines, standards SYSTEMATIC REVIEW Table 1 List of publications that were included in the review ALt, alanine aminotransferase; cK, creatinine kinase; cPA, collaborative practice agreement; egFr, estimated glomerular filtration rate; FLP, fasting lipid profile; HbA1c, hemoglobin A1c; LDL, lowdensity lipoprotein; LIs, laboratory information system; MtM, medication therapy management; rct, randomized controlled trial. Table 1 (continued) SYSTEMATIC REVIEW and frameworks (6), descriptive articles/reviews (5) and position statements (2).
Ability to access laboratory tests
Primary care pharmacists' access to laboratory data varies depending on jurisdiction (Table 2) .
Canada. Pharmacists in the provinces of Alberta, Quebec, Nova Scotia and New Brunswick in Canada have the authority to access laboratory data, [22] [23] [24] [25] although the standards for Nova Scotia do not specify how the relevant laboratory data are obtained by the pharmacist after they have been ordered, despite being required to forward the laboratory results to relevant health professionals if needed. 22 In Saskatchewan, pharmacists can only access laboratory data that have been ordered within a collaborative practice agreement. 26 In Alberta, all pharmacists can access all laboratory data through a province-wide system called Netcare. 23 Leung et al. 27 surveyed Canadian community pharmacists to understand changes in digital health and the impact this had on practice. They reported that 23% of pharmacists have access to laboratory test results through a laboratory information system (LIS), with 57% of them experiencing an increase in productivity because of this access and 87% indicating better or much better quality of patient care. Australia. Australia currently has no published literature defining primary care pharmacists' access to laboratory data. Only where an established pharmacist-patient professional relationship is present and once it has been determined that the laboratory tests will not be duplicating tests previously ordered by another health care professional.
h As an independent prescribing pharmacist. 
SYSTEMATIC REVIEW
However, the extent of the supplementary prescribing pharmacists' scope of practice is determined by an independent prescriber (e.g., physician or dentist) and defined by an agreedupon patient-specific clinical management plan in consultation with the patient. 33 For both independent and supplementary prescribing pharmacists, the standards and guidelines have specified that they require verbal or written consent from the patient to order laboratory tests for the purpose of excluding contraindications, clarifying doses or noting treatment cautions. 33 Bourne et al. 38 surveyed UK independent prescribing critical care pharmacists to determine their current and proposed future scope of practice in this setting. The authors found that therapeutic drug monitoring was routine practice among this sample of pharmacists.
New Zealand. In New Zealand, the prescribing pharmacists framework indicates that they have the authority to order and interpret laboratory tests within a collaborative health team environment, although there is a lack of literature describing the extent of this practice.
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Australia. Australia currently has no published literature defining primary care pharmacists' authority to order laboratory tests. Figure 2 provides a comparison of primary care pharmacists' scope of practice in relation to laboratory testing within the 5 reviewed countries. Among these countries, we estimated that 35%, 0%, 4%, 0.3% and 0% of primary care pharmacists in Canada, the United States, the United Kingdom, New Zealand and Australia, respectively, are able to provide care that includes independent laboratory testing (Figure 3 ).
Availability to patients
39-49
Interventional and qualitative studies There are limited interventional and qualitative studies evaluating and describing pharmacists' scope of practice in relation to ordering laboratory tests. One study, conducted in Canada by Al Hamarneh et al. 50 in 2016, found that when pharmacists' scope of practice included laboratory testing, previously unrecognized chronic kidney disease was uncovered in 40% of highrisk patients. This highlights the potential of ordering laboratory testing to positively affect SYSTEMATIC REVIEW patient care and outcomes. However, the other interventional and qualitative studies included in this review only mentioned that pharmacists were ordering and interpreting laboratory data and did not explicitly evaluate the benefits of this for patients, pharmacists, other health care professionals and/or the health care system. [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] In the few studies that do describe the scope of practice, the extent of the description is only of the types and frequency of tests ordered. 
Improvements in patient outcomes
Currently, there is a lack of interventional and qualitative studies explicitly evaluating whether using primary care pharmacists' full scope of practice (including laboratory testing) improves patient outcomes, with all studies included in this review being conducted in either Canada or the United States. Nonetheless, the majority of studies that mentioned pharmacists accessing and ordering laboratory data, in some capacity, resulted in positive patient outcomes (Table 4) .
Canada. The majority of literature from Canada, which involved pharmacists independently accessing and ordering laboratory tests, showed positive patient outcomes, which ranged from reducing the risk of cardiovascular disease (CVD) events, uncovering unrecognized chronic kidney disease (CKD), reducing blood pressure (BP) and achieving target lipid levels. 50, 57, 58, 63 McKinnon and Jorgenson 56 showed positive patient outcomes through an improvement in patient medication management when the pharmacists accessed and ordered laboratory tests dependently, as well. 56 On the other hand, Villeneuve et al. 62 reported no significant Pharmacists dependently accessed and order laboratory tests.
difference in lipid control when compared to usual care without physician-pharmacist collaboration, when pharmacists could access and order laboratory data independently. 62 United States. In the United States, all primary care pharmacists accessed and ordered laboratory data dependently within a collaborative practice agreement. The majority of these studies found positive patient outcomes, including improvement in glycemic control and diabetesrelated health maintenance, a reduction in BP, a reduction in long-term CVD risk and an improvement in patient satisfaction. [53] [54] [55] 59, 60, 64 However, Heisler et al. 52 reported shortterm improvements in lowering BP but no difference in BP, HbA1c and LDL levels between intervention and control in the long run when they evaluated a targeted pharmacist-led management program to improve BP, which included the ordering of HbA1c and LDL laboratory tests for patients with diabetes and persistent hypertension. 52 Furthermore, a study by Cooney et al. 51 evaluated the effect of a pharmacist-based quality improvement program on CKD patient outcomes and adherence to CKD guidelines, which involved the ordering of eGFR, proteinuria, PTH, phosphorus and urine microalbumin-creatinine ratio laboratory tests to improve BP. This study showed no significant improvements in BP but did find an overall improvement in adherence to guidelines.
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Discussion
Patients around the world deserve to receive a full scope of pharmacist services-this includes prescribing, disease management, injections and laboratory testing. 13 To our knowledge, this is the first review to explore primary care pharmacists' scope of practice in relation to laboratory testing. Primary care pharmacists' full scope of practice is not being fully used in most jurisdictions when it comes to laboratory testing, and when it is used, it is often in a dependent fashion. Overall, the limited literature indicates that certain jurisdictions of Canada have defined guidelines allowing pharmacists to access and order laboratory tests in primary care settings such as community pharmacies, within primary care teams in health centres or as part of a collaborative practice agreement with a physician. 22 In New Zealand, prescribing pharmacists order and interpret laboratory tests within collaborative health teams. 9 At present, Australia has no published literature defining primary care pharmacists' scope of practice in laboratory testing. Such services have the potential to improve patient outcomes by facilitating prescribing and potentially reducing medication-related errors, but it seems to be limited to only a few jurisdictions and often only in a dependent fashion.
Pharmacists' scope of practice in relation to prescribing medications, as well as the positive impact this has on patient outcomes and satisfaction, has been previously described and evaluated. 28, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] 63 Despite a shift towards full utilization of pharmacists' scope with the inclusion of prescribing, access to laboratory testing has not yet been widely incorporated, and so there is a gap that limits the evaluation and description of pharmacists' scope of practice. This is evident by the established prescribing frameworks, standards and/or guidelines for pharmacists in the United States, Canada, the United Kingdom and New Zealand. 9, 29, 30, 33, 65, 66 In contrast, there are limited subsequent frameworks, standards and/ or guidelines for pharmacists specific to laboratory testing across and within these countries. This review has highlighted not only the need for the adoption of coherent policies for pharmacists who participate in laboratory testing but also the importance of laboratory testing for patients to receive a full scope of pharmacists' services. A full scope of practice promotes patient-centred care via collaborative practice with other health care professionals when implemented. Furthermore, improved patient outcomes and economic benefits with a full scope of practice for pharmacists have previously been described and evaluated. 28, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] 63, 67 The current scope of practice markedly limits patients' access to primary care pharmacists who can provide laboratory testing services. We estimated that 2.93, 0, 0.24, 0.02 and 0 primary care pharmacists per 10,000 Canadians, Americans, British, New Zealanders and Australians, respectively, can provide care that includes independent laboratory testing. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Practically speaking, this means that in the countries reviewed, only 0% to 35% of primary care pharmacists can provide care that includes laboratory testing. Due to this limited scope of practice in laboratory testing, as well as the paucity of literature, it is difficult to ascertain the true extent of primary care pharmacists' current scope of practice. A lack of published interventional studies meant that several questionnaire and survey studies were included in this review. Furthermore, this review follows a systematic method. It encompasses some elements of a systematic review, such as predefined inclusion and exclusion criteria and a comprehensive search of select databases. However, it does not critically analyze the quality of the literature and includes grey literature. A meta-analysis, applying the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, was unable to be performed due to the nature of this review, specifically a lack of substantial publications, with the majority being grey literature. Moreover, this review included a grey literature search, which may not have returned all the relevant publications. It also focused on 5 countries (Canada, United States, United Kingdom, New Zealand and Australia) and did not include publications prior to 2007. Therefore, critical publications with the potential to reveal important insights may not have been captured in the search. Future reviews could focus on expanding these criteria. These limitations must be considered when interpreting the findings of this review.
Practice implications
Primary care pharmacists' involvement in laboratory testing has the potential to improve patient outcomes. This review has identified that only a few jurisdictions in the United States, Canada, the United Kingdom and New Zealand have authorized their primary care pharmacists to access and perform laboratory testing, which is patient centred and promotes collaborative practices. As such, there is a need for pharmacists to pursue laboratory testing in order to be able to provide a full scope of practice for their patients. There is also a need for standards, guidelines and frameworks to support those jurisdictions that are lacking in these policies SYSTEMATIC REVIEW and for future research focusing on evaluating related outcomes.
Conclusion
Primary care pharmacists' scope of practice in relation to laboratory testing is presently limited to certain jurisdictions and often occurs only in a dependent fashion. As such, a full scope of pharmacy services is almost entirely unavailable to patients in the United States, the United Kingdom, New Zealand and Australia. Just as in the case for pharmacist prescribing, evidence indicates better patient outcomes when pharmacists can access/order laboratory tests, but more research needs to be done alongside the implementation of local guidelines and practice standards for primary care pharmacists who are participating in laboratory testing. ■
